Myeloid Disease Diagnosis
Myeloid Disease Diagnosis - Related Videos
09:20
Microwave Assisted Rapid Diagnosis of Plant Virus Diseases by Transmission Electron Microscopy
0 Views •
Cited by 16 •
2011
This study describes a method that allows the rapid and clear diagnosis of plant virus diseases in about half a day by using a combination of microwave assisted plant sample preparation for transmission electron microscopy and negative staining methods.
07:34
FISH for Pre-implantation Genetic Diagnosis
0 Views •
Cited by 17 •
2011
This article describes the selection of suitable probes for single-cell FISH, spreading techniques for blastomere nuclei, and in situ hybridization and signal scoring, applied to pre-implantation genetic diagnosis (PGD) in a clinical setting.
06:39
Culture of myeloid dendritic cells from bone marrow precursors
0 Views •
Cited by 22 •
2008
This video demonstrates the procedure for differentiating myeloid dendritic cells from mouse bone marrow. Isolation of mouse tibia and femur, and processing of bone marrow are demonstrated. Pictures demonstrating cell morphology before and after differentiation, and figures depicting cell phenotype and IL-12 production following maturation using CpG are shown.
06:23
The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
0 Views •
Cited by 68 •
2016
This article describes the 4 Mountains Test (4MT), a hippocampus-dependent test of working allocentric spatial memory. The hippocampus is affected early in Alzheimer's disease (AD) and this article outlines the 4MT methodology and results of patient testing, which demonstrates the value of the 4MT in the diagnosis of pre-dementia AD.
05:14
Studying Interactions between Myeloid Cells and CAR T Cells In Vitro and In Vivo
0 Views •
2025
Given the limited xenograft models available to study interactions between human CART and myeloid cells, we established in vitro and in vivo models to understand the impacts of human macrophages on CART cells. Findings can potentially be generalized to evaluate macrophage roles in the tumor microenvironment and test macrophage-targeted immunotherapies.
FAQs
Interpretation depends on combining clinical findings with cellular, chromosomal, and molecular evidence. Different myeloid disorders can produce similar symptoms or abnormal blood counts, so no single result necessarily establishes the disease category. Integrating these sources helps clinicians recognize abnormal cell populations, identify lineage patterns, distinguish overlapping conditions, and develop a more reliable basis for risk assessment and treatment selection.
Complete blood counts describe abnormalities in circulating blood cells, while peripheral-blood smears allow direct review of their appearance and distribution. Bone marrow assessment examines the blood-forming tissue more directly. Flow cytometry characterizes abnormal cell populations and lineage, whereas cytogenetic and molecular tests identify chromosomal changes or disease-associated mutations. Together, these tests provide complementary rather than interchangeable information.
Lineage patterns indicate which blood-forming cell populations are abnormal, helping separate disorders that may share broad clinical features. Cytogenetics adds information about chromosomal changes, and molecular testing detects disease-associated mutations. Considering these findings together supports more precise classification when several leukemias, myelodysplastic syndromes, or myeloproliferative neoplasms present with overlapping symptoms or blood-count abnormalities.
The evaluation commonly begins with medical history and physical examination, followed by a complete blood count and peripheral-blood smear review. If further characterization is needed, clinicians assess bone marrow and apply flow cytometry, cytogenetics, or molecular testing. This progression moves from overall clinical and blood findings toward increasingly specific cellular, chromosomal, and molecular evidence for classification.
Bone marrow assessment is important when circulating blood findings do not provide enough information to characterize the abnormal process. It examines the tissue where blood-forming cells arise, complementing the complete blood count and smear. Its findings can then be integrated with flow cytometry, cytogenetics, and molecular testing to clarify abnormal populations, lineage patterns, and disease classification.
Diagnostic results provide more than an initial disease label. Classification and risk assessment help inform treatment selection, while integrated laboratory findings can be compared during follow-up to monitor response or progression. Because the evaluation includes cellular, chromosomal, and molecular information, repeated assessment can track changes across several levels rather than relying only on symptoms or blood counts.
In clinical medicine, accurate classification supports increasingly precise, patient-specific hematologic care by linking disease features with risk and treatment decisions. In research, the same combination of cell-population, lineage, chromosomal, and molecular findings helps investigate disease mechanisms. This shared diagnostic framework connects routine evaluation with efforts to understand how myeloid disorders arise and change.